3-[1-(2-Morpholin-4-yl-ethyl)-1H-indol-3-yl]-propionic acid | 850895-27-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 3-[1-(2-Morpholin-4-yl-ethyl)-1H-indol-3-yl]-propionic acid
• CAS: 850895-27-1
• 化学式: C₁₇H₂₂N₂O₃
• 分子量: 302.373
• InChiKey: NNPSQXSGBQLLJC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.99
• 重原子数：
  22.0
• 可旋转键数：
  6.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  54.7
• 氢给体数：
  1.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  4-氨基吡啶 、 3-[1-(2-Morpholin-4-yl-ethyl)-1H-indol-3-yl]-propionic acid 在 2-氯-1-甲基吡啶碘化物 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 3-[1-(2-Morpholin-4-yl-ethyl)-1H-indol-3-yl]-N-pyridin-4-yl-propionamide
  参考文献：
  名称：

  New N-pyridinyl(methyl)-indolalkanamides acting as topical inflammation inhibitors

  摘要：

  The authors have described the synthetic way to new N-pyridinyl(methyl)indolylpropanamides acting as non acidic NSAIDs. Pharmacomodulation was carried out at N-1 and C-5 of the indole ring and at the level of the propanamide chain. N-(pyridin-3-ylmethyl)-3-[5-chloro-1-(4-chlorobenzyl)-indol-3-yl]propanamide 32 represents one of the most potent compounds evaluated in the TPA-induced mouse ear swelling assay, with a level of activity higher than that of ibuprofen and comparable to that of dexamethasone. (C) 2004 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2004.07.057
• 作为产物：
  描述：

  3-[1-(2-Morpholin-4-yl-ethyl)-1H-indol-3-yl]-propionic acid ethyl ester 在 sodium hydroxide 作用下， 以 乙醇 为溶剂， 生成 3-[1-(2-Morpholin-4-yl-ethyl)-1H-indol-3-yl]-propionic acid
  参考文献：
  名称：

  New N-pyridinyl(methyl)-indolalkanamides acting as topical inflammation inhibitors

  摘要：

  The authors have described the synthetic way to new N-pyridinyl(methyl)indolylpropanamides acting as non acidic NSAIDs. Pharmacomodulation was carried out at N-1 and C-5 of the indole ring and at the level of the propanamide chain. N-(pyridin-3-ylmethyl)-3-[5-chloro-1-(4-chlorobenzyl)-indol-3-yl]propanamide 32 represents one of the most potent compounds evaluated in the TPA-induced mouse ear swelling assay, with a level of activity higher than that of ibuprofen and comparable to that of dexamethasone. (C) 2004 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2004.07.057